Improved cancer diagnostic imaging is one step closer to reality with the sale of Combidex® by an American pharmaceutical company to a Dutch university that intends to launch global trials, reports the International Strategic Cancer Alliance. Combidex® is a nanoparticle fluid used with magnetic resonance imaging (MRI) that can visualize cancer metastases with pinpoint accuracy in lymph nodes as small as 2 - 3 millimeters, compared to conventional CT imaging, which can only visualize malignant nodes that are larger than 8 millimeters.
(PRWeb April 08, 2013)
Read the full story at http://www.prweb.com/releases/2013/4/prweb10600077.htm
